Virion Therapeutics
Newark
About Virion Therapeutics
Virion Therapeutics is a science-driven company developing innovative immune-based treatments for virally associated cancers and chronic viral infections. Their vaccines, ChiVax and ChiVax-gD, represent novel and highly effective platforms to induce potently and sustained T cell-mediated immune responses against transformed or infected cells, thereby targets common diseases with unmet medical needs. Each component comprising chimeric vaccine candidates has completed pre-clinical testing that allows for their translation into clinical trials for several different indications. Guided by their scientific and management expertise, these platforms may help cure such devastating diseases as HPV-induced cancers and chronic Hepatitis B infections. Virion Therapeutics was founded in 2018 and is headquartered in Newark, Delaware.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.2M
- Last round: Undisclosed (Oct 2024)
- Website: viriontx.com
- Phone: 800-841-9303
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/virion-therapeutics-47621 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.